Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.

Ann Hematol. 2011 Jan;90(1):89-94. doi: 10.1007/s00277-010-1036-8. Epub 2010 Aug 13.

PMID:
20706722
2.

Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.

Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P.

Eur J Haematol. 2006 Nov;77(5):410-5. Epub 2006 Aug 23.

PMID:
16930141
4.

Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.

Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G.

Transfusion. 2006 Aug;46(8):1417-23.

PMID:
16934080
5.

Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.

Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.

Clin Ther. 2009;31 Pt 2:2388-95. doi: 10.1016/j.clinthera.2009.11.013.

PMID:
20110048
6.
7.

Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.

Gerds A, Fox-Geiman M, Dawravoo K, Rodriguez T, Toor A, Smith S, Kiley K, Fletcher-Gonzalez D, Hicks C, Stiff P.

Biol Blood Marrow Transplant. 2010 May;16(5):678-85. doi: 10.1016/j.bbmt.2009.12.531. Epub 2010 Jan 4.

8.

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.

Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.

Bone Marrow Transplant. 2005 Jun;35(12):1165-9.

PMID:
15880129
9.
11.

Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F.

Oncology. 2010;79(1-2):93-7. doi: 10.1159/000320604. Epub 2010 Nov 15.

PMID:
21079406
12.

Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.

Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD.

Bone Marrow Transplant. 2010 Oct;45(10):1522-7. doi: 10.1038/bmt.2009.373. Epub 2010 Jan 11.

PMID:
20062102
13.

Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.

Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):186-91. doi: 10.3816/CLML.2010.n.029.

PMID:
20511163
15.

Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.

Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.

Appl Health Econ Health Policy. 2013 Apr;11(2):129-38. doi: 10.1007/s40258-013-0011-7.

PMID:
23435861
16.

A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.

Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, Perry G, Genest P, Huebsch L.

Bone Marrow Transplant. 1998 Nov;22(10):965-9.

17.

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.

Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.

Am J Hematol. 2006 Dec;81(12):973-8.

18.

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.

Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M.

Haematologica. 2008 Nov;93(11):1739-42. doi: 10.3324/haematol.13204. Epub 2008 Aug 25.

19.

Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.

Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G.

Bone Marrow Transplant. 2005 Jan;35(1):33-6.

PMID:
15531906
20.

Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.

Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T, Zeller LW, Moehler T, Ho AD, Goldschmidt H.

Bone Marrow Transplant. 2007 Jun;39(12):743-50. Epub 2007 Apr 23.

PMID:
17450182
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk